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Despite decreases in the cancer death rates in high-resource
countries, such as the USA, the number of cancer cases and
deaths is projected to more than double worldwide over the next
20–40 years. Cancer is now the third leading cause of death, with
>12 million new cases and 7.6 million cancer deaths estimated to
have occurred globally in 2007 (1). By 2030, it is projected that
there will be  26 million new cancer cases and 17 million cancer
deaths per year. The projected increase will be driven largely by
growth and aging of populations and will be largest in low- and
medium-resource countries. Under current trends, increased
longevity in developing countries will nearly triple the number
of people who survive to age 65 by 2050. This demographic shift
is compounded by the entrenchment of modiﬁable risk factors
such as smoking and obesity in many low-and medium-resource
countries and by the slower decline in cancers related to chronic
infections (especially stomach, liver and uterine cervix) in eco-
nomically developing than in industrialized countries. This pa-
per identiﬁes several preventive measures that offer the most
feasible approach to mitigate the anticipated global increase in
cancer in countries that can least afford it. Foremost among these
are the need to strengthen efforts in international tobacco control
and to increase the availability of vaccines against hepatitis B
and human papilloma virus in countries where they are most
needed.
Introduction
Cancer is now the third leading cause of death worldwide, with .12
million new cases and 7.6 million cancer deaths estimated to have
occurred in 2007 (1). By 2030, it is projected that there will be  26
million new cancer cases and 17 million cancer deaths per year (2).
Moreover, the global distribution of cancer and types of cancer that
predominate continues to change, especially in economically devel-
oping countries. Low- and middle-income countries accounted for
about half (51%) of all cancers worldwide in 1975; this proportion
increased to 55% in 2007 and is projected to reach 61% by 2050 (3).
Cancers of the lung, breast, colon/rectum and prostate are no longer
largely conﬁned to Western industrialized countries but are among the
most common cancers worldwide.
This global increase in the cancer burden and its disproportionate
impact on economically developing countries is being propelled by
both demographic changes in the populations at risk and by temporal
and geographic shifts in the distribution of major risk factors. The
three most important factors that contribute to these trends are:
1. Growth and aging of populations;
2. The entrenchment of modiﬁable risk factors (particularly ciga-
rette smoking, Western diet and physical inactivity) in developing
countries and
3. The slower decline in cancers related to infectious etiologies in
low-resource countries than in high-resource countries.
The ﬁrst of these largely reﬂects progress in reducing death rates
from acute infectious conditions among children and young adults.
Unfortunately, this has not historically been matched by parallel
efforts to control the major modiﬁable risk factors that cause cancer
and other chronic diseases. Given the magnitude of the projected de-
mographic trends and their disproportionate impact on countries that
can least afford increased health care expenditures, preventive meas-
ures offer the most feasible approach. This paper identiﬁes several
preventive measures that could mitigate the expected increase in the
number of people affected by cancer over the next 20–40 years.
Foremost among these are the need to strengthen efforts in interna-
tional tobacco control and to increase the availability of vaccines
against hepatitis B virus (HBV) and human papilloma virus (HPV)
in countries where they are most needed. Both tobacco control and
universal childhood vaccination have been proven to be highly effec-
tive and cost effective in countries across a wide range of economic
development. Both have the potential to provide the greatest beneﬁt at
the lowest cost.
Global population changes
P o p u l a t i o ng r o w t ha n da g i n ga r et h el a r g e s tc o n t r i b u t o r st ot h e
increasing total number of cancer cases and the shift in the burden
of cancer and other chronic diseases toward economically develop-
i n gc o u n t r i e s .T h ew o r l dp o p u l a t i o ni n2 0 0 8w a s6 . 7b i l l i o n .B a r r i n g
a catastrophe, this number is expected to increase to 8.3 billion
in 2030 (2) and to 8.9 billion by 2050 (3). Figure 1 illustrates that
the projected population growth will be much larger in low- and
medium-resource countries than in high-resource countries, even
in older age groups. For example, the number of people age
65 and above in low- and medium-resource countries is expected
to increase from 247 million to 982 million between the year
2000 and 2050. The corresponding increase in people age 65 and
above in high-resource countries will be from 171 million to 376
million. Aging of populations will disproportionately affect
the number of people who develop or die from cancer since almost
half (45%) of cancers diagnosed worldwide in 2002 occurred in
people .65 years of age (3).
Estimates of the future impact of population growth and aging on
the global cancer burden depend on assumptions about the anticipated
changes in cancer incidence rates as well as changes in the underlying
population at risk.However, itis more difﬁcult to predict global trends
in incidence rates than to project demographic changes because the
information on cancer incidence rates is limited or non-existent for
large areas of the world and there is great variation among countries.
Hence, some projections of the future cancer burden assume that the
global cancer incidence rates will remain constant over time and that
the number of cancer cases and deaths will be affected only by growth
and aging of the population. For example, Figure 2 illustrates the
expected global increase in incident cancer cases from 2002 to
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incidence rate, the number of cases anticipated in 2050 (24 million)
would be more than twice the number in 2002 (10.8 million). Most of
this increase would occur in low- and middle-resource countries (3).
By comparison, the number of cancers that the International Agency
for Research on Cancer projects by 2030 (26 million) is substantially
higher than the estimate in Figure 2 (18.9 million) because the In-
ternational Agency for Research on Cancer assumes a 1% annual
increase in the incidence rate as well as the anticipated demographic
changes in the population at risk (2).
Tobacco use and prevention of tobacco-related cancers
Tobacco use is the single largest preventable cause of cancer and
premature death worldwide. An estimated 1.3 billion people in the
world currently smoke tobacco; the vast majority of these smoke
manufactured cigarettes (4). If current trends in smoking and popu-
lation growth continue, the number of current smokers is expected to
reach 2 billion worldwide by 2030 (5). As shown in Figure 3, smoking
prevalence is highest among men in Eastern Europe, the former Soviet
Union, China and Indonesia. Cigarette smoking among women has
been decreasing in most high-resource countries but is stable or
increasing in several countries in Southern, Central and Eastern
Europe (4). With the decline of tobacco use in many industrialized
countries, the geography of smoking has shifted from the developed
to the developing world, especially for men. About 50% of men and
9% of women are current smokers in developing countries, com-
pared with 35% of men and 22% of women in high-resource coun-
tries (4). Over 60% of all smokers in the world live in just 10
countries (in order): China, India, Indonesia, Russian Federation,
USA, Japan, Brazil, Bangladesh, Germany and Turkey (6). The
number of current smokers in China approximately equals the entire
population of the USA. While most of these smokers are currently
under age 40, the combination of continued smoking and aging will
vastly increase the future adverse effects of tobacco use on cancer
and other chronic diseases, unless effective campaigns can be
mounted to promote cessation.
The International Agency for Research on Cancer designates at
least 15 different types or subtypes of cancer as causally related to
smoking (7). These include cancers of the lung and bronchus (all
histological subtypes), larynx, oral cavity, pharynx, lip, nasopharynx,
nasal cavity and paranasal sinuses, esophagus (squamous and adeno-
carcinoma), bladder, kidney (parenchyma and renal pelvis), pancreas,
uterine cervix, stomach, liver and acute myeloid leukemia (7).
Cancers attributed to cigarette smoking accounted for more than
one-ﬁfth of the estimated 1.42 million cancer deaths that occurred
globally in the year 2000 (8). Lung cancer is the most common cancer
caused by smoking, even though it accounts for less than half of all
smoking-attributable deaths (9). Cigarette smoking accounts for
 80% of lung cancer cases in men and 50% in women worldwide
(5). Lung cancer has been the most common cancer in the world since
1985 (10).
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Fig. 1. Growth and aging of world population, 2000 and 2050 by gender and level of economic development.
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Fig. 2. Number and distribution of cancer cases by level of economic
development and year assuming no change in the annual incidence rate.
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101In many countries, temporal trends in smoking, and more recently
in smoking cessation, have been so extreme that they have dominated
national trends in cancer mortality (9). For example, the downturn in
death rates from smoking-related cancers in men, ages 65–69 that
began in the UK in the early 1960s, in the USA in the mid-1980s
and in Poland in the early 1990s, has been the major driver in the
downturn in death rates from all cancers combined in these countries
(9). This has occurred despite the delay that occurs between reduc-
tions in smoking prevalence and reductions in lung cancer mortality,
seen when comparing Figures 3 and 4 for men in North America and
Western Europe. Progress in reducing male lung cancer rates was
achieved principally by smoking cessation among adult men.
Unfortunately, cessation rates are much lower in large developing
countries like China than in the West. In China, many millions of
young cigarette smokers who began smoking in adolescence are
now aging. The future risks of cancer or other diseases caused by
smoking may eventually be greater among these younger generations
of Chinese men who began smoking in childhood than those now seen
among Chinese smokers who initiated smoking later in life (9).
Despite this bleak picture, much progress can and is being made to
reduce tobacco smoking, especially in high-resource countries. In the
USA, per capita cigarette consumption has decreased to levels not
seen since the start of World War II. Projections based on data from
the Food and Agriculture Organization of the United Nations indicate
that tobacco consumption will continue to fall in economically de-
veloped countries but will rise in most low- and medium-resource
countries (11). A number of interventions have proven to be effective
in reducing the demand for tobacco products and in changing social
norms about smoking. Tax policies that raise the price of tobacco
products are the single most effective approach for reducing demand.
Price increases are an especially powerful deterrent against the initi-
ation of smoking in youth (12,13,14) and motivation for addicted
smokers to quit. Although the impact of price on cigarette demand
varies widely depending on the population studied and study design,
a 10% increase in cigarette prices result in a 2.5–5% reduction in
cigarette demand in high-resource countries. Estimates of price
responsiveness in low- and middle-income countries are at least as
large (15).
Smoke-free laws that prohibit smoking in public places substan-
tially reduce non-smokers’ exposures to secondhand smoke, change
social norms about smoking and motivate smokers to quit. Successful
smoke-free interventions by Ireland and other countries have greatly
broadened the protection of non-smokers. Public awareness about the
harmful effects of tobacco on health can be increased by requiring
prominent, graphical warnings on cigarette packaging (16) and by
educational campaigns aimed at health professionals. These are
Fig. 3. Prevalence of male and female smoking by geographic region.
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102especially important in low- and medium-resource countries, where
baseline levels of awareness about the extent of tobacco’s deleterious
effects are low and doctors still smoke. In China, 61.3% of
male physicians smoke, compared with 66.9% of the general male
population.
Many of the adverse health effects of smoking can be averted by
cessation. Smoking cessation is the only effective way to reduce risk
for the 1.3 billion smokers in the world. As mentioned above, wide-
spread smoking cessation among men in high-income countries since
the 1950s is largely responsible for the signiﬁcant decrease in death
rates from lung and other smoking-related cancers in these countries.
Although pharmacological treatment is less affordable in economi-
cally developing than in high-resource countries, brief counseling
interventions by health care personnel are feasible. Counseling about
smoking cessation can be integrated into other public health and
health care delivery programs, such as tuberculosis, human immuno-
deﬁciency virus (HIV)/AIDS, family planning and maternal health
programs.
No single country can successfully combat the resources of the
international tobacco companies. Thus, nations have united behind
the Framework Convention on Tobacco Control (FCTC), the ﬁrst
health treaty negotiated under the auspices of the World Health
Organization (WHO). The FCTC provides a framework for national
legislation and enforcement of tobacco control measures. The FCTC
was promulgated in May 2003 in response to the global tobacco
pandemic with the objective of substantially reducing the worldwide
prevalence of tobacco use and exposure to tobacco smoke. As of
August 2009, 166 countries have ratiﬁed the treaty, representing
 80% of the world’s population. FCTC provisions establish interna-
tional standards for tobacco taxation, advertising and sponsorship,
regulation, trade, etc. Effective measures against smuggling are espe-
cially important. Estimates suggest that 6–8% of cigarettes consumed
globally are contraband products, shipped to avoid taxes. Smuggling
can be deterred by prominent tax stamps that cannot be counterfeited
easily, local language warnings on cigarette packs and aggressive
enforcement of anti-smuggling measures and penalties.
Diet, obesity and physical inactivity
Like tobacco, obesity, physical inactivity and poor nutrition are estab-
lished causes of several types of cancer. Rapid increases in the prev-
alence of obesity (deﬁned by WHO as body mass index.30 inadults)
have occurred in the USA since the 1970s and more globally since the
1980s (17). Thetrend toward overweight andobesity is evengreater in
Fig. 4. Lung cancer incidence in males and females.
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103children than in adults and has occurred not only in high-resource
countries but also in urban and even rural areas of many low- and
middle-income countries (17). WHO estimates that the number of
overweight adults (age .15) in 2005 was  1.6 billion, of whom
300 million were obese. The number of overweight was projected
to increase to 2.3 billion by 2015 (18).
The global increase in overweight and obesity is attributed to in-
creased availability of calorie-dense foods and decreased physical
activity. Food supplies have become more plentiful and foods, espe-
cially processed foods, have become more energy dense in fats and
sugars (17). Coinciding with this, humans have become more seden-
tary as mechanization has eliminated much of the need for involuntary
physical activity. Excess adiposity, especially visceral adiposity, is
known to increase risk of a variety of cancers, including breast (post-
menopausal), endometrium, colon/rectum, esophagus (adenocarci-
noma) and kidney. Despite the negative health, social and economic
consequences of obesity, efforts are just beginning to develop solu-
tions to the problem. People who have gained weight generally have
great difﬁculty losing it and maintaining weight loss. There is great
interest in identifying policy measures to help people maintain
a healthy weight throughout life. However, research in this area is
currently at an early developmental stage and evaluation of these
methods is ongoing.
Cancers related to chronic infections
Persistent infection with various microbial organisms accounts for
 18% of cancers worldwide (19). The most common malignancies
caused by chronic infections are cancer of the uterine cervix, stomach
and liver, caused by HPV, Helicobacter pylori (H.pylori) and HBV
and Hepatitis C (HCV) virus, respectively (Table I). Several other
cancer sites related to infectious agents that occur mostly regionally
are also listed in Table I. These include Kaposi’s sarcoma (KS) caused
by human herpes virus 8 (HHV-8), nasopharyngeal cancer and certain
lymphomas from Epstein Barr virus (EBV), bladder cancer from
Schistosoma haematobium, leukemia from human t-cell lympho-
tropic virus and biliary tract cancer from onchocerciasis.
In terms of global patterns, the incidence rates from cancers of
the stomach and liver have been falling in most countries world-
wide, although the decrease has been slower in low- and medium-
resource countries than in the West. The percentage of cancers
attributed to infections remains about three times higher in devel-
oping (26%) than in developed (8%) countries (20). For most can-
cers related to infectious organisms, chronic inﬂammation is an
important component of pathogenesis. Some viruses incorporate
their genetic material directly into host cell DNA (21). The remain-
ing sections of this paper will focus on the most common infection-
related cancers for which vaccines and other preventive approaches
are available.
HPV-related cancers
Cervical cancer is the second most common cancer among women
worldwide, with an estimated 555 000 new cases and 310 000 deaths
in 2007. About 80% of cervical cancer cases occur in developing
countries where, in many regions, it is the most common cancer
among women (2). Although the age-standardized incidence rate is
considerably lower in Asia than in Central America, Asia accounts for
more than half of theworld’s cervical cancer cases and deaths because
of its immense population.
Incidence and mortality rates for cervical cancer in developed
countries have decreased dramatically in the past 25 years, due largely
to cervical cancer screening using Pap tests, which allows for detec-
tion and treatment of precancerous lesions. The incidence and death
rates remain high in countries that cannot afford cytologic screening,
where oncogenic strains of HPV are still common. Worldwide, the
highest incidence rates are in South America and the Caribbean, Sub-
Saharan Africa and South and Southeastern Asia. The disproportion-
ate burden of cervical cancer on developing countries is due mainly to
lack of resources for cervical cancer screening.
Virtually, all cases of cervical cancer result from recurrent cervical
infections with HPV (22). About 40 HPV viral types have been found
to infect the anogenital tract (23). A recent pooled analysis of case–
control studies from nine countries identiﬁed 15 HPV types that are
associated with an increased risk of cervical cancer. Among these
types, HPV 16 and HPV 18 have the highest prevalence among
cervical cancer patients (50.5 and 13.1%, respectively) and are asso-
ciated with a .200-fold increased risk of cervical cancer (24). Al-
though infection with HPV (types 16 and 18 in particular) greatly
increase the risk of developing cervical cancer, such infection is com-
mon and most infected women do not develop cervical cancer. The
prevalence of HPV infection among women as measured among
women without cervical cancer measured in a recent international
study was 15.5%, with 5% being positive for HPV types 16 or 18.
The cumulative lifetime probability of acquiring a cervical infection
with at least one type of HPV is extremely high for sexually active
individuals. However, most HPV infections disappear spontaneously
within 2–4 years, and only a small percentage progress to low- and
high-grade squamous intraepithelial lesions. High-grade squamous
intraepithelial lesion, which includes carcinoma in situ, may progress
to invasive cancer if not detected and treated. Factors that may
inﬂuence progression include immunosupression, smoking, increas-
ing parity (number of children) and coinfection with herpes simplex
virus or chlamydia (25).
Table I. The burden of cancer caused by Infectious agents worldwide
Infectious agent IARC
classiﬁcation
a
Cancer site/cancer Number of
cancer cases
Percentage of cancer
cases worldwide
Helicobacter pylori 1 Stomach 490 000 5.4
HPV 1, 2A Cervix and other sites 550 000 6.1
HBV, HCV 1 Liver 390 000 4.3
EBV 1 Lymphomas and nasopharyngeal carcinoma 99 000 1.1
HHV-8 2A KS 54 000 0.6
Schistosoma haematobium 1 Bladder 9000 0.1
HTLV-1 1 Leukemia 2700 0.1
Liver ﬂukes Cholangiocarcinoma (biliary system) 800
Opisthorchis viverrini 1
Clonochis sinensis 2A
Total infection-related cancer 1 600 000 17.7
Total cancer in 1995 9 000 000 100
HTLV-1, human t-cell lymphotropic virus.
Source: World Cancer Report 2008 (2).
aGroup 1 5 carcinogenic to humans; Group 2A 5 probably carcinogenic to humans.
M.J.Thun et al.
104In addition to cervical cancer, HPV infection is associated with
vulvar carcinoma, some oral carcinomas, penile carcinoma and anal
carcinoma. The anus is similar to the cervix in that both have a trans-
formation zone that is susceptible to HPV infection. The risk of anal
carcinoma is increased among men who have sex with men (26).
Primary prevention
Recently developed cervical cancer vaccines have the potential to
prevent HPV infection; however, effective vaccines against HPV in-
fection are too costly to be available in high-risk areas. Consequently,
negotiations for tiered pricing must reduce the cost from about $360
per woman and identify alternative sources offunding if thevaccine is
to be made available in the areas of greatest need in the next 10–20
years.
Although some HPV subtypes cause genital warts, most infections
with HPV cause no symptoms. Since HPV can be present in skin
throughout the anogenital area as well as in genital secretions, use of
condoms may be somewhat but not completely protective (26). Circum-
cision apparently reduces the risk of transmission and acquisition of
HPVas well as the risk of cervical cancer among female partners (26).
Detection of high-grade squamous intraepithelial lesion and carci-
noma in situ by Pap testing, with effective treatment of precancerous
lesions, is currently the most effective way to prevent cervical cancer.
Pap testing is not available to most women in developing countries.
Barriers to Pap testing in developing countries are substantial and
include lack of public health and medical infrastructure to organize
population screening and follow-up, as well as the high level of ex-
pertize and quality control needed to ensure accuracy of cytologic
diagnosis. In some countries, cultural taboos may also prevent women
from seeking orreceivingappropriate screening from male health care
providers. Development and evaluation of alternative screening strat-
egies for use in developing countries has been a high priority for
international health agencies. Visual inspection of the cervix after
applying acetic acid is one cost-effective technique (27). Training
and employing midwivesand other female health workers offers some
potential for overcoming cultural barriers.
Secondary prevention
In addition to preventing invasive cervical cancer, Pap testing can
detect cervical cancer at an early stage, when it is most readily treated.
Fig. 5. Liver cancer incidence in males and females.
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105Liver cancer, HBV and hepatitis C virus
Liver cancer is the ﬁfth most common cancer in men and the eighth
most common in women (1). An estimated 711 000 cases of primary
liver cancer occured worldwide in 2007; about three-quarters of these
are hepatocellular carcinoma (HCC). Liver cancer is the third leading
cause of cancer death worldwide with an estimated 680 000 deaths
occurring in 2007. More than 80% of cases occur in developing coun-
tries; .55% occur in China alone. Figure 5 illustrates that liver cancer
incidence rates are highest in West and Central Africa and in Asia,
especially among men.
Globally,  75% of all liver cancer cases and 50% of all deaths are
caused by chronic infection with either HBVor HCV (1). The fraction
of cases attributable to HBV is greater in developing countries (59%)
than in developed countries (23%) The corresponding percentages for
HCV are 33 and 20%, respectively (1). Both HBV and HCV are di-
rectly transmitted by person-to-person contact with blood or other
body ﬂuids. Hepatitis A, another common agent of viral hepatitis, is
usually transmitted through contaminated food and does not cause
liver cancer.
A safe and effective vaccine against HBV has been available since
1982. Novaccine has yet been developedfor HCV, which accounts for
 10% of liver cancer deaths worldwide. Vaccination for HBV is the
most cost-effective strategy to reduce liver cancer. Effective vaccina-
tion programs could avert at least 300 000 liver cancer deaths per
year. The cost of the vaccine has been reduced from $100 to $1 (for
three doses of treatment) through the efforts of the Global Alliance
for Vaccines and Immunization. Over three-quarters of WHO member
states have introduced hepatitis B vaccine into routine infant immu-
nization schedules, although inmanyplaces it is difﬁcult to deliverthe
vaccine within 24 h of birth. Vaccine delivery is particularly challeng-
ing in high risk, low-resource areas of Africa.
HBV
Approximately 54% of liver cancer worldwide is attributed to chronic
infection with HBV (20). Chronic (long term) infection with HBV is
indicated by persistence of hepatitis B surface antigen (a marker of
active Hepatitis B infection) in the blood after the acute infection has
passed. The probability of developing chronic infection is much high-
er for infants and children than for adults. People with chronic in-
fection are also referred to as ‘chronic carriers’ because they are able
to infect others. Among people who have had HBV infection, only
those with chronic infection are at increased risk of developing
chronic liver disease, cirrhosis and liver cancer (28).
About 350 million people in the world today (29), and 1.25 million
people in the USA (30), are chronic carriers of HBV. HBV may be
transmitted by mucous membrane or skin contact only when there are
breaks (even small and insigniﬁcant ones) in these barriers. It may be
transmitted by injection or sexual intercourse or pass from a mother to
her baby during birth. Because HBV is able to remain infectious for
about a week on any surface, minute exposures from sharing of tooth-
brushes, razors and other items in household settings can result in
transmission (31). An importantcause of HBVinfection in developing
countries is reuse of syringes or needles between patients without
sterilization. An estimated 20% of new HBV infections worldwide,
or 8–16 million infections per year, arise from unsafe injections in
medical care settings (32).
In high-prevalence areas of the world, HBV infection in  70% of
cases is acquired at birth or in early childhood. In industrialized
countries, infection more often occurs in adolescence and young
adulthood and is associated with high-risk behaviors such as injection
drug use and multiple sex partners. Health care workers and patients
with exposure to pooled blood products, such as hemophiliacs, are
also at increased risk.
The exact mechanism by which HBV infection causes HCC is un-
known. Tumor cells of patients with liver cancer often have DNA
from HBV inserted into cellular DNA. Inﬂammation and scarring of
the liver (cirrhosis) may contribute to malignant transformation.
Although 60–90% of patients with HCC due to chronic HBV have
cirrhosis, it is possible to develop HCC without cirrhosis (33). Expo-
sure to aﬂatoxins (toxic products of mold in grains and other foods
products) may be a signiﬁcant cofactor in localized areas (34).
Primary prevention. Three doses of vaccine against HBVare needed
to achieve adequate long-term immunity. It is recommended that all
infants, unvaccinated adolescents and adults in high-risk groups re-
ceive the vaccine. The ﬁrst dose for infants should be administered
within 24 h. This is difﬁcult in many parts of the worlds since about
half of all babies born worldwide are born at home. In countries such
as Indonesia, however, trained birth attendants have been taught to
administer the vaccine to babies at home. It is also recommended that
all pregnant women be tested for HBV carrier status; if positive, the
newborn infant receives Hepatitis B immune globulin as well as Hep-
atitis B vaccine within 12 h after birth (35). This treatment is highly
effective in preventing infection in newborns.
In high-resource countries, vaccination of infants and children and
screening of blood donors for HBV surface antigen have greatly
decreased the incidence of acute HBV, especially among people under
the age of 20 (30,31). The burden of HBVinfection and resulting liver
disease and HCC is much greater in the developing world than in
developed countries due to greater barriers to prevention. Although
the WHO recommends HBV vaccination for all infants, many poor
countries have been unable to implement this recommendation due to
the cost of obtaining and administering the vaccine. In 1999, a com-
mitment by the Bill and Melinda Gates Foundation of $750 million
over 5 years led to the development of the Global Alliance for
Vaccines and Immunization , an international partnership created to
improve access to sustainable immunization services.
Screening of blood products and sterilization of injection equip-
ment is essential to reduce HBV transmission in medical settings.
Another potential way to reduce the incidence of HCC in some de-
veloping countries is to reduce consumption of foods contaminated
with aﬂatoxins, which may contribute to the development of HCC
among HBV carriers. Preventing aﬂatoxin contamination of the food
supply can be accomplished by implementing changes in pre-and
post-harvest agricultural practices and dietary patterns (34).
Secondary prevention. No treatment has been proven to be effective
in preventing progression to chronic liver disease and HCC among
HBV carriers. Treatment with a-interferon or lamivudine reduces
viral replication in some patients but the improvement is often tran-
sient (31,36). A recent study of treatment with Vitamin K showed
some promise in reducing liver cancer rates among women with cir-
rhosis (37).
There have been no randomized controlled trials to evaluate the
cost or efﬁcacy of screening for liver cancer in chronic HBV carriers.
In the USA, many physicians screen healthy carriers yearly or twice
yearly for high levels of serum a-fetoprotein. Carriers with additional
risk factors, including active chronic hepatitis or cirrhosis, are
screened twice yearly with serum a-fetoprotein measurement and
ultrasound (38).
HCV
About 31% of liver cancer worldwide is attributed to HCV compared
with 8% in North America (20). First identiﬁed in 1988, HCV was
conﬁrmed as the major cause of ‘non-A, non-B’ hepatitis in 1990 (39).
Although HCV infection can cause symptoms similar to HBV, the
majority of newly infected people have no symptoms. A person
infectedwithHCVhasover an80%probabilityofbecomingachronic
carrier. Worldwide, 170 million persons are infected with HCV, and
the global prevalence of HCVinfection is 3.1%, ranging from 1.0% in
Europe to 5.3% in Africa (40).
Direct transmission by blood contamination, usually though a nee-
dle, is the most important mode of HCV transmission. In the USA,
60% of chronic HCVinfections are attributed to intravenous drug use,
15% to receipt of blood transfusions before 1989 (when a test to
M.J.Thun et al.
106screen for HCV in donated blood became available) and 15% to
sexual transmission (41). The rate of acquisition of HCV infection
among intravenous drug users is very high, with a number of studies
showing 20–40% being infected within the ﬁrst year of using needles
(42). HCV infection occurs in 3–8% of health care workers who
experience needlestick exposures to HCV-infected patients and in
2–8% of infants born to mothers with active HCV infection (31).
Approximately 50% of infants are able to eradicate the disease with
no intervention. Post-exposure prophylaxis with immunoglobulin has
not been proven effective in preventing HCVinfection among infants
or adults (43).
A decline in the rate of HCV infection in developed countries has
been attributed to changes in the blood donor population and
transfusion practice, mandatory screening of donated blood and a
decline in injection drug use (44). Although liver cancer incidence
increased in some developed countries such as the USA during the
same time, this increase is thought to be due to the aging of the
population previously infected (45).
About 25% of people with chronic HCV infection will develop
hepatic ﬁbrosis that evolves into cirrhosis. Among those who develop
cirrhosis, liver cancer develops at a rate of 1–4% per year. Cofactors
that may inﬂuence this progression are alcohol intake, age at infection
and coinfection with HBVor HIV (43).
In developing countries, use of unscreened blood and blood prod-
ucts and reuse of injection equipment in medical settings are major
routes of HCV transmission (42).
Primary prevention. There is no vaccine available for HCV. In most
developed countries and in some developing countries, the main route
of transmission is intravenous drug use. Needle and syringe exchange
programs have been shown, in a limited number of studies, to reduce
rates of HCV infection (42). Universal precautions (a set of precau-
tions designed to prevent transmission of blood-borne pathogens
when providing ﬁrst aid or health care) and safer needle design have
reduced risks of infection among health care workers.
The Centers for Disease Control and Prevention recommend that
routine HCV testing be offered to individuals in high-risk groups,
although this practice may not be feasible in developing countries.
Individuals who test positive are provided medical referral and coun-
seling to reduce the risk of HCV transmission to others (44).
Other important elements of primary prevention are screening of
donated blood and blood products for antibody to HCVand instituting
infection control practices during all medical, surgical and dental
procedures. While these measures are particularly important in parts
of the world with high prevalence of HBV and HCV, they have not
been implemented in many developing countries due to resource
constraints (42).
Secondary prevention. Patients with HCV should be evaluated to
determine the extent of their liver disease, and if appropriate, receive
counseling to limit their alcohol intake, receive anti-viral treatment,
immunization with hepatitis A, hepatitis B, pneumococcal and inﬂu-
enza vaccines and treatment for drug or alcohol abuse. Treatment with
a-interferon and ribavirin produces sustained response rates (meaning
that HCV RNA is undetectable at 24 weeks after therapy) of 54–56%,
with a low probability of subsequent relapse (43), and reduces the
incidence of liver cancer among sustained responders (46). However,
there are numerous adverse effects and contraindications to this treat-
ment and the high cost makes it unaffordable for most HCV carriers in
developing countries (43).
Other infection-related cancers
A number ofother chronic infectionsare knownto causevarious types
of cancer. Although these were not included among the top priorities
for prevention, they do contribute substantially to the cancer burden in
certain geographic areas and are discussed brieﬂy below.
H.pylori and stomach cancer
Incidence and death rates from stomach cancer have steadily declined
over the last 50 years, even though stomach cancer remains the fourth
most common malignancy, and is second only to lung cancer as the
leading cause of cancer deaths (10). Stomach cancer accounted for
.1 million estimated cases and 800 230 deaths in 2007, with an
estimated 60% of new cases occur in developing countries (1, 2).
Despite falling incidence rates, the number of new cases and deaths
continues to increaseglobally because of population growth and aging
in high-risk countries. Risks are generally highest in Asia (Korea,
Japan and China) and parts of Central and South America (Costa Rica,
El Salvador and Columbia) and lowest in North America and most of
Africa.
Chronic or recurrent infection with H.pylori is the main cause of
chronic gastritis and peptic ulcers and increases risk for developing
gastric lymphoma and cancer of the distal stomach (47). H.pylori is
a spiral, gram-negative bacterium that colonizes the stomach. It is not
known with absolute certainty how H.pylori is transmitted, but the
most probable route of spread from person to person is through fecal-
oral or oral-oral routes. Possible environmental reservoirs include
contaminated water sources. Based on prevalence surveys conducted
in the USA in 1988–1991, about one-third of adults had evidence of
H.pylori infection (48). Prevalence increased steadily with increasing
age, peaking at .50% among persons age  50. In developing coun-
tries, the age at onset of infection is generally lower and peaks at
.90% among young adults (47).
The exact causes of the worldwide decline in gastric cancer inci-
dence in the past decades are not known but are thought to include
improvements in diet, food storage and a decline in H.pylori infection
due to a general improvement in sanitary conditions and increasing
use of antibiotics (49, 50). The eradication of H.pylori in asymptom-
atic carriers has been proposed as a potential method to prevent stom-
ach cancer. Trials of the efﬁcacy of this approach in preventing the
development of atrophic gastritis should be conducted in high-risk
areas. However, this approach does not preclude the existing practice
of screening for gastric cancer in high-risk populations.
Primary prevention. Since the source of H.pylori is not yet known,
recommendations for avoiding infection have not been made. In gen-
eral, it is always wise for persons to wash hands thoroughly, to eat
food that has been properly prepared and to drink water from a safe,
clean source. Trials of H.pylori eradication in high-risk populations
have been attempted. Treatment with bismuth salts, amoxicillin and
clarithromycin is currently the regimen of choice; however, subopti-
mal results (clearance of infection in ,50% of persons treated) have
been observed in some studies. Eradication will also be ineffective in
preventing stomach cancer if people are rapidly reinfected (47). There
is concern that extensive use of antibiotics may lead to antibiotic
resistant strains of H.pylori or other pathogens (51). Chemoprevention
trials using vitamin supplements have shown some promise and ad-
ditional trials are underway (47).
Efforts are also underway to develop an H.pylori vaccine, but trials
have thus far been disappointing (51). Furthermore, it has been hy-
pothesized that the reduction in gastric acid secretion due to H.pylori
infection may protect against the adverse effects of gastroesophageal
reﬂux disease such as Barrett esophagus and adenocarcinoma of the
gastric cardia and esophagus. Efforts to eradicate H.pylori with anti-
biotic treatment or vaccination should consider the potential risks as
well as beneﬁts (50).
Secondary prevention. Screening for stomach cancer has been prac-
ticedinJapan(wheretheincidenceofstomachcancerisaboutsixtimes
higher than the incidence in the USA) since 1963. The main screening
technique used in Japan is indirect X-ray examination by the double
contrast method. Record linkage between participants in the screening
and a population-based cancer registry indicate that the sensitivity
(abilitytoidentifycorrectlythosewhohavethedisease)andspeciﬁcity
(ability to identify correctly those who do not have the disease) of this
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ulation screening and perhaps greater awareness of early symptoms
and alowthreshold fordiagnostic evaluation, 50% ofstomach cancers
in Japan are diagnosed at a localized stage, and the overall 5 year
survival has increased from 20% in 1962 to 40% in 1992. Over the
same time period, the 5 year survival rate in the USA remained stable
at 20% (53). Although general population screening is not recommen-
ded in low-incidence countries such as the USA, a low threshold for
testing symptomatic individuals may be warranted.
KS, HHV-8 and HIV
It is estimated that 77 600 new cases of KS occurred worldwide in
2005. KS has been common in central Africa since the early 20th
century, and was also found in some Mediterranean countries and the
Middle East, but was rare elsewhere. It was also observed in devel-
oped countries among immigrants from endemic areas, recipients of
organ transplants and patients with immune suppression from chemo-
therapeutic drugs. In 1981, an aggressive form of KS began to appear
in the USA among homosexual men, one of the ﬁrst signals of the
AIDS epidemic (54).
Only one of the four subtypes of KS is associated with AIDS. The
AIDS-related KS has identical histopathology to the other subtypes; it
is more probable to involve multiple lesions and worse prognosis. In
areas of Africa where KS was relatively common before the AIDS
epidemic, the incidence of KS has increased  20-fold. In several
African countries (Malawi, Swaziland, Uganda and Zimbawe), it is
now the most common cancer in men and the second most common
cancer in women (54).
It is now thought that infection with HHV-8 (also known as KS-
associated herpes virus), rather than the AIDS virus itself, is the
principal cause of KS. Sexual contact is thought to be the major mode
of transmission of HHV-8. HHV-8 prevalence increases steadily with
age among children in Africa, indicating that alternate modes of trans-
mission exist (54).
In the USA, the risk of KS among men having sex with men is
much greater than among other persons infected with HIV (55). The
incidence of KS peaked among men age 20–54 in 1989 and then
declined markedly. Since highly active antiretroviral therapy
(HAART) did not become widely available in the USA until 1996,
some of this decline is probably due tochanges in sexualpractices that
reduced transmission of both HIV and HHV-8 (55,56). KS rates
peaked somewhat later (1991–1996) among African-American men,
and when ﬁrst reported in 1992, rates among Hispanics were higher
than among white and African-American men. Incidence rates among
all ﬁve racial and ethnic groups declined from 1992 to 2001 but show
some evidence of stabilizing in the past 3–4 years.
Primary prevention
The most effective methods for preventing KS are those that protect
against exposure to HIV and HHV-8. Preventive behaviors include
sexual abstinence, sex only with an uninfected partner, consistent
and correct condom use, abstinence from injection drug use and con-
sistent use of sterile equipment by those unable to cease injection drug
use (57). Similar precautions are recommended for those who are
already HIV positive, both to prevent infecting others and to avoid
infection with other sexually transmitted and blood-borne diseases.
There is some evidence that progression to KS might be accelerated
among persons who become infected with HHV-8 after being infected
with HIV (58).
Secondary prevention
HAART treatment reduces the risk of KS among patients infected
with HIV and may also be effective in treating the tumors (55). In
2003, the WHO estimated that 6 million people in developing coun-
tries needed immediate HAART and ,8% would get it. On World
AIDS Day in 2003, the WHO launched ‘The 3 by 5 Initiative’, whose
goal is to provide antiretroviral treatment to 3 million people in
developing countries by 2005 (11).
HIV, EBV and non-Hodgkin’s lymphoma
It is estimated that there were 300 000 new cases of non-Hodgkin’s
lymphoma (NHL) worldwide in 2007. NHL is an extremely varied
group of neoplasms. Some forms of NHL, including Burkitt’s lym-
phoma, are associated with EBV. Most people are infected with EBV
at sometime in their lives. When infection occurs during adolescence
or young adulthood, it causes infectious mononucleosis 35–50% of
the time. EBV infection is also associated with some AIDS-related
NHL and Hodgkin’s lymphoma.
AIDS-related NHL is generally aggressive, high-grade lymphomas
of B-cell origin. They include primary central nervous system
lymphomas, high-grade immunoblastic and Burkitt’s lymphoma,
and to a lesser extent, intermediate-grade large cell diffuse lympho-
mas. Unlike KS, which occurs primarily in men who have sex with
men, all HIV risk groups, including intravenous drug users and
children of HIV-positive individuals have equivalent risks of AIDS-
related NHL. The diagnosis of AIDS precedes the onset of NHL in
57% of patients, but in 30% of cases, the diagnosis of AIDS is made at
the same time as NHL and HIV positivity. In general, the clinical
course of patients with AIDS-related lymphoma is more aggressive,
and the disease is more extensive and less responsive to therapy than
that of non-HIV patients with non-Hodgkin’s lymphoma (59).
There has also been some evidence of an increased risk of Hodgkin’s
lymphoma among HIV-infected individuals, but the evidence is less
strong (59).
Primary prevention
Primary prevention of AIDS-related lymphomas rests on primary pre-
vention of HIV infection, as described under KS. Since EBV is trans-
mitted through contact with saliva, and may be present in saliva of
healthy people, there are no methods for primary prevention of EBV
infection.
Secondary prevention
Some AIDS-related lymphomas are associated with high levels of
immunosuppression, as reﬂected by very low CD4 counts. The in-
cidence of primary central nervous system lymphoma, which is asso-
ciated with very low CD4 counts, fell rapidly after introduction of
HAART therapy, whereas the incidence of intermediate type lym-
phoma has remained stable since 1995. Overall, epidemiologic data
show that the risk of AIDS-related lymphoma has decreased  50%
with HAART therapy, but risk is unchanged within groups of patients
stratiﬁed by CD4 count. As the proportion of patients receiving
HAART therapy has increased, there has been a shift to higher CD4
strata, with a change in the distribution of lymphoma types. Those
lymphomas that do occur are more responsive to treatment, which
may account for recent trends of improved survival for AIDS-related
NHL (60).
Conclusions
In summary, preventive measures provide the only feasible approach
to slow and ultimately reverse the global increase in cancer and its
disproportionate impact on countries that can least afford it. We have
emphasized why national and international efforts to strengthen to-
bacco control and to make childhood vaccination against HBV and
HPV universally available and affordable in countries where these
infections are prevalent should be among the highest priorities. Suc-
cessful implementation of these programs will require both national
leadership and international collaboration to overcome the economic
and political barriers that often impede public health. It will also
require action-oriented translational research to adapt programs that
have proven to be effective in high-income countries to every setting
in which they are needed.
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